Associate Professor Michael Holmes
Michael Holmes
BSc(Hons) MBBS MSc(Epidemiology) PhD MRCP
Associate Professor
- Clinical Trial Service Unit and Epidemiological Studies Unit
Michael Holmes studied Medicine at University of St Andrews and University College London, graduating in 2005. Working in the NHS as a hospital physician, he held NIHR clinical academic posts including academic foundation year and an academic clinical fellowship in Clinical Pharmacology and Therapeutics/General Internal Medicine. Michael then undertook a Masters in Epidemiology at London School of Hygiene and Tropical Medicine and completed a PhD in Genetic Epidemiology at University College London. Following his PhD, he was Assistant Professor at University of Pennsylvania, Philadelphia, USA, where he investigated genetic determinants of clinical outcomes following organ transplantation.
Michael is a Senior Clinical Research Fellow in Cardiovascular Medicine at CTSU. He is working within the China Kadoorie Biobank (CKB) to investigate causal risk factors underpinning cardiovascular disease and cancer subtypes. Michael's expertise lies in using genetic variants to disentangle causality from confounding with the aim of improving understanding of disease aetiology and identifying novel therapeutic targets for disease prevention.
Recent publications
-
Sex Differences in the Risk of Coronary Heart Disease Associated With Type 2 Diabetes: A Mendelian Randomization Analysis.
Journal article
Peters TM. et al, (2020), Diabetes Care
-
Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases.
Journal article
Pang Y. et al, (2020), JAMA Cardiol
-
Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.
Journal article
Watts EL. et al, (2020), Int J Cancer
-
Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200,000 men in UK Biobank
Journal article
Watts EL. et al, (2020), International Journal of Cancer
-
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19.
Journal article
Bovijn J. et al, (2020), Lancet Rheumatol, 2, e658 - e659